Jul 29, 2021 by Kody KesterHow AbbVie Could Make an Entry Into This Rapidly Growing Drug MarketVenclexta's potential indication for the treatment of myelodysplastic syndrome could mean billions for AbbVie this decade.
Jul 29, 2021 by Kody KesterAfter Naming a New CFO, Is This Genetic Diagnostics Company a Buy?Veracyte appointed Rebecca Chambers, who boasts a wealth of financial executive experience, to the position.
Jul 28, 2021 by Kody KesterCould Medtronic's Surgical Robotics Business Be a Growth Catalyst?The medical device company's Hugo robotic-assisted surgery (RAS) system may end up playing a significant role in its growth.
Jul 18, 2021 by Kody KesterAfter Beating Estimates, Is This Little-Known Medical Device Company a Buy?AngioDynamics exceeded analyst expectations on revenue in Q4 2021, but does that make it worth buying?
Jul 17, 2021 by Kody KesterWith the Alexion Acquisition Set to Close This Quarter, Is AstraZeneca a Buy?With UK approval, the $39 billion deal for rare disorders biotech company Alexion Pharmaceuticals is set to close on July 21.
Jul 15, 2021 by Kody KesterIs This Surgical Robotics Company a Cheap Buy Now?After Asensus Surgical joined the Russell 2000 index last month, the stock climbed higher but has since fallen back to earth.
Jul 12, 2021 by Kody KesterShould Investors Consider This Expanding Healthcare Business After Its Massive Dividend Hike?Did LeMaitre Vascular jeopardize its payout with its recent 16% dividend lift?
Jul 10, 2021 by Kody KesterIs Trupanion Still a Buy After the Rally in June?The company doubled down on its commitment to growth targets with its creation of an International Business EVP position.
Jul 8, 2021 by Kody KesterThis Ultra-Safe Dividend Stock Looks Like a Solid Buy After a 9% BoostThe healthcare behemoth's payout increase was in line with investor expectations, but can it afford the increased dividend cost?
Jul 8, 2021 by Kody KesterUp 6% in June, Is Accelerate Diagnostics a Good Buy Now?Investors were encouraged by a recent award the company received in the effort to diagnose and treat sepsis more rapidly.
Jun 30, 2021 by Kody KesterAbbVie: Is the Price Right for Long-Term Investment?The pharma giant's stock is up 18% in the past year. Have investors missed the boat or is the stock still a buy?
Jun 23, 2021 by Kody KesterDoes Johnson & Johnson Have the Safest Dividend in Healthcare?Could this longstanding Dividend King have the least risky payout in the sector?
Jun 16, 2021 by Kody KesterIs UnitedHealth's Dividend Safe After a 16% Increase?The healthcare giant's payout hike exceeded expectations, but can it afford the expense?
